SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hyrulean King who wrote (281)6/12/1998 10:10:00 AM
From: Lee Walsh   of 5402
 
FROM SEC Filings:

PHER-O2 is believed to have the following advantages over humanblood:
1. May carry three to four times the oxygen of human blood per unit
2. Free of HIV, hepatitis and other blood-borne disease;
3. Universal match for all blood types;
4. May be mass-produced;
5. Has a three-year shelf life;
6. May be stored at room temperature;
7. Has controllable circulatory half-life; and
8. 1/900th the size of a red blood cell.
9. PHER-O2 is a second generation drug from Fluosol-DA, the only
synthetic red blood cell approved by the Food and Drug Administration.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News